By Julia Karow

Faced with limited revenue, upcoming debt payments, and a dwindling amount of cash, Helicos BioSciences' outlook for 2012 remains bleak, despite the firm's recent cost-cutting measures.

Earlier this week, Helicos reported $725,000 in third-quarter revenue and a $798,000 net loss for the quarter. As of Nov. 1, it had $1.6 million in total available resources, including $275,000 in cash and equivalents and $1.33 million from a bridge debt financing facility it secured last year.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In PLOS this week: genes under positive selection in Plasmodium falciparum populations, genetic variation in Epstein-Barr viruses, and more.

Cancer clinical trial patients settle with Anil Potti and Duke University.

A trio of researchers is trying to raise money to sequence and analyze the genome of a cat with a suite of unusual traits.

Two Johns Hopkins researchers discuss the need for evidence-based data analysis.